Clinical Trials Browser

Uveal Melanoma, Melanoma, Neoplasms, Ovarian Neoplasms, Recurrence

NCT03025256 2026-05-05

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase 1 Recruiting

75 enrolled

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Terminated

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Phase 1 Not yet recruiting

15 enrolled

Dermatologic

Uveal Melanoma

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT05987332 2026-02-17

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Phase 2/3 Active not recruiting

420 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT04552223 2026-02-11

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Phase 2 Completed

27 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Phase 1 Terminated

67 enrolled

Dermatologic

Uveal Melanoma

NCT04283890 2025-09-09

CHOPIN

Phase 1/2 Active not recruiting

83 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT05004025 2025-08-15

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Phase 1 Completed

10 enrolled

Dermatologic

Uveal Melanoma

NCT03922880 2025-05-15

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Phase 1 Completed

9 enrolled

Dermatologic

Uveal Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Phase 2 Completed

14 enrolled 8 charts

Dermatologic

Uveal Melanoma

NCT04463368 2025-03-28

SCANDIUM II

Phase 1 Completed

18 enrolled

Dermatologic

Uveal Melanoma

NCT06519266 2024-11-25

SCANDIUM-III

Phase 3 Recruiting

40 enrolled

Dermatologic

Uveal Melanoma

NCT05169957 2024-11-05

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Phase 1 Completed

2 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 2 Completed

67 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

Phase 2 Completed

53 enrolled 10 charts

Dermatologic

Uveal Melanoma, Melanoma

NCT02831933 2023-09-21

ENSIGN

Phase 2 Terminated

11 enrolled 9 charts

DermatologicThoracic

Uveal Melanoma, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT03528408 2023-04-11

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Phase 2 Unknown

52 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT02626962 2022-03-22

GEM1402

Phase 2 Completed

52 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT02913417 2021-04-19

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Phase 1/2 Unknown

26 enrolled

Dermatologic

Uveal Melanoma

NCT03326258 2018-07-18

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Phase 1/2 Withdrawn

BreastDermatologic

Uveal Melanoma, Breast Neoplasms, Melanoma, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Clinical Trials

ACTengine

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

CHOPIN

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

SCANDIUM II

SCANDIUM-III

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Neoadjuvant and Adjuvant Checkpoint Blockade

ENSIGN

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

GEM1402

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery